Andrew B. Tobin
Glasgow, SCT G128QQ, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 115 publications
Low Agonism and Balanced Pathway Modulation Distinguish an M1 Muscarinic Receptor Positive Allosteric Modulator Lacking Cholinergic Adverse Effects.
Journal: ACS chemical neuroscience
Published: June 30, 2026
Allosteric ligands with distinct properties uncover tissue-specific physiological regulation mediated by free fatty acid receptor 2.
Journal: Science signaling
Published: June 30, 2026
Inhibition of PfCLK3 interferes with malaria parasite RNA splicing and explains the mechanism of action of a new class of antimalarial candidates.
Journal: Antimicrobial agents and chemotherapy
Published: June 27, 2026
Erratum: Wide-field and non-invasive imaging of brain tumours with scattered light techniques: erratum.
Journal: Biomedical optics express
Published: March 04, 2026
Shaping Antimalarials: A Geometry-First Approach to PfCLK3 Covalent Inhibitors.
Journal: Journal of medicinal chemistry
Published: January 31, 2026
Dogma-defying signalling through G proteins could lead to better pain relief.
Journal: Nature
Published: December 18, 2025
Wide-field and non-invasive imaging of brain tumours with scattered light techniques.
Journal: Biomedical optics express
Published: December 10, 2025
Physiological Significance of Endothelial M3 Muscarinic Receptors During Exercise.
Journal: Circulation research
Published: July 16, 2025
Lysine targeting covalent inhibitors of malarial kinase PfCLK3.
Journal: RSC medicinal chemistry
Published: April 17, 2025
Optical, contact-free assessment of brain tissue stiffness and neurodegeneration.
Journal: Biomedical optics express
Published: October 28, 2024
Targeting PfCLK3 with Covalent Inhibitors: A Novel Strategy for Malaria Treatment.
Journal: Journal of medicinal chemistry
Published: October 23, 2024
Last Updated: 09/26/2026